Logo image of AVTX

AVALO THERAPEUTICS INC (AVTX) Stock Fundamental Analysis

NASDAQ:AVTX - Nasdaq - US05338F3064 - Common Stock - Currency: USD

8.44  +1.28 (+17.88%)

Fundamental Rating

2

Overall AVTX gets a fundamental rating of 2 out of 10. We evaluated AVTX against 572 industry peers in the Biotechnology industry. AVTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AVTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AVTX has reported negative net income.
AVTX had a negative operating cash flow in the past year.
In the past 5 years AVTX always reported negative net income.
In the past 5 years AVTX always reported negative operating cash flow.
AVTX Yearly Net Income VS EBIT VS OCF VS FCFAVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M

1.2 Ratios

With a decent Return On Assets value of -35.87%, AVTX is doing good in the industry, outperforming 60.92% of the companies in the same industry.
AVTX has a Return On Equity of -155.34%. This is in the lower half of the industry: AVTX underperforms 65.90% of its industry peers.
Industry RankSector Rank
ROA -35.87%
ROE -155.34%
ROIC N/A
ROA(3y)-126.77%
ROA(5y)-113.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVTX Yearly ROA, ROE, ROICAVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

1.3 Margins

AVTX has a Gross Margin of 191.95%. This is amongst the best in the industry. AVTX outperforms 99.47% of its industry peers.
AVTX's Gross Margin has declined in the last couple of years.
AVTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 191.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.65%
GM growth 5Y-9.11%
AVTX Yearly Profit, Operating, Gross MarginsAVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

5

2. Health

2.1 Basic Checks

AVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
AVTX has less shares outstanding than it did 1 year ago.
AVTX has less shares outstanding than it did 5 years ago.
There is no outstanding debt for AVTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVTX Yearly Shares OutstandingAVTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
AVTX Yearly Total Debt VS Total AssetsAVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

AVTX has an Altman-Z score of -4.97. This is a bad value and indicates that AVTX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.97, AVTX is doing worse than 61.46% of the companies in the same industry.
AVTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.97
ROIC/WACCN/A
WACC10.46%
AVTX Yearly LT Debt VS Equity VS FCFAVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M

2.3 Liquidity

A Current Ratio of 1.42 indicates that AVTX should not have too much problems paying its short term obligations.
With a Current ratio value of 1.42, AVTX is not doing good in the industry: 83.13% of the companies in the same industry are doing better.
AVTX has a Quick Ratio of 1.42. This is a normal value and indicates that AVTX is financially healthy and should not expect problems in meeting its short term obligations.
AVTX's Quick ratio of 1.42 is on the low side compared to the rest of the industry. AVTX is outperformed by 82.24% of its industry peers.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 1.42
AVTX Yearly Current Assets VS Current LiabilitesAVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

2

3. Growth

3.1 Past

AVTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.16%, which is quite impressive.
Looking at the last year, AVTX shows a very negative growth in Revenue. The Revenue has decreased by -63.72% in the last year.
The Revenue for AVTX have been decreasing by -22.83% on average. This is quite bad
EPS 1Y (TTM)56.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.27%
Revenue 1Y (TTM)-63.72%
Revenue growth 3Y-34.03%
Revenue growth 5Y-22.83%
Sales Q2Q%5.51%

3.2 Future

The Earnings Per Share is expected to grow by 15.09% on average over the next years. This is quite good.
Based on estimates for the next years, AVTX will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y95.78%
EPS Next 2Y41.03%
EPS Next 3Y25.8%
EPS Next 5Y15.09%
Revenue Next Year-87.51%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AVTX Yearly Revenue VS EstimatesAVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
AVTX Yearly EPS VS EstimatesAVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2K -4K -6K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVTX. In the last year negative earnings were reported.
Also next year AVTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVTX Price Earnings VS Forward Price EarningsAVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVTX Per share dataAVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200 -250

4.3 Compensation for Growth

AVTX's earnings are expected to grow with 25.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.03%
EPS Next 3Y25.8%

More info and screens

0

5. Dividend

5.1 Amount

AVTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVALO THERAPEUTICS INC

NASDAQ:AVTX (2/21/2025, 8:02:25 PM)

8.44

+1.28 (+17.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-27 2025-03-27/amc
Inst Owners63.55%
Inst Owner Change-93.51%
Ins Owners5.29%
Ins Owner Change0%
Market Cap87.69M
Analysts84
Price Target33.66 (298.82%)
Short Float %0.49%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-54.43%
Min EPS beat(2)-105.88%
Max EPS beat(2)-2.98%
EPS beat(4)0
Avg EPS beat(4)-3499.35%
Min EPS beat(4)-11614.9%
Max EPS beat(4)-2.98%
EPS beat(8)3
Avg EPS beat(8)-1738.06%
EPS beat(12)6
Avg EPS beat(12)-1149.73%
EPS beat(16)7
Avg EPS beat(16)-867.07%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.71%
EPS NQ rev (1m)-27.35%
EPS NQ rev (3m)-27.35%
EPS NY rev (1m)44.59%
EPS NY rev (3m)6.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 106.94
P/FCF N/A
P/OCF N/A
P/B 3.86
P/tB 7.17
EV/EBITDA N/A
EPS(TTM)-272.53
EYN/A
EPS(NY)-5.42
Fwd EYN/A
FCF(TTM)-3.54
FCFYN/A
OCF(TTM)-3.54
OCFYN/A
SpS0.08
BVpS2.19
TBVpS1.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.87%
ROE -155.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 191.95%
FCFM N/A
ROA(3y)-126.77%
ROA(5y)-113.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.65%
GM growth 5Y-9.11%
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.44%
Cap/Sales 0.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.42
Quick Ratio 1.42
Altman-Z -4.97
F-Score3
WACC10.46%
ROIC/WACCN/A
Cap/Depr(3y)55.15%
Cap/Depr(5y)35.08%
Cap/Sales(3y)3.6%
Cap/Sales(5y)3.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.27%
EPS Next Y95.78%
EPS Next 2Y41.03%
EPS Next 3Y25.8%
EPS Next 5Y15.09%
Revenue 1Y (TTM)-63.72%
Revenue growth 3Y-34.03%
Revenue growth 5Y-22.83%
Sales Q2Q%5.51%
Revenue Next Year-87.51%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-27.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.84%
OCF growth 3YN/A
OCF growth 5YN/A